OGT Initiates Strategic Expansion Plans in North America
News Nov 20, 2012
Oxford Gene Technology (OGT) has announced that it has opened a new office in Tarrytown, New York to support and grow its CytoSure™ cytogenetics arrays and Genefficiency™ next generation sequencing business in the US.
The new office will enable OGT to provide hands-on technical support and training to its existing US customers, and to take advantage of opportunities to develop the business further.
A number of Sales and Support positions including a Field Application Specialist have been created with more new roles expected in the coming months.
OGT has CytoSure and Genefficiency customers in over 30 countries worldwide and serves a potential clinical cytogenetics market of $400million with rapid future growth forecast.
The US is the world’s largest cytogenetics market, and is critical to the development of OGT’s clinical and genomic services business.
Dr Mike Evans, CEO at OGT said, “The opening of the New York office marks a significant milestone for OGT allowing us to offer our US customers even better technical and sales support. Meeting the needs of our customers is our top priority, in a recent survey, 100% of our CytoSure customers said they would recommend OGT to a colleague and we are committed to both continuing and building on this level of expertise and support”.
Dr Madhuri Hegde from Emory University School of Medicine said, “We are delighted that OGT has opened a new US office. The company has a strong reputation and we have always received exceptional service, we look forward to working with the new local support team.”
CytoSure products and Genefficiency services combine advanced microarray and sequencing solutions with class-leading analysis software, enabling clinicians and researchers to accurately detect and interpret chromosomal abnormalities.
The CytoSure range focuses on constitutional genetics, molecular genetics and cancer cytogenetics and is a strong growth area for OGT with an increasing global market share.
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE